Overview

Osteoarthritis Pain Drugs Market is forecasted to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

FutureWise Market Research has illustrated a report that provides an in-depth anatomy of the market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The Osteoarthritis Pain Drugs market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Osteoarthritis Pain Drugs market are:   

• Abbott Laboratories 
• Johnson & Johnson 
• Novartis International 
• Pfizer
• Abiogen Pharma 
• Afferent Pharmaceuticals 
• Astellas Pharma 
• BioDelivery Sciences International
• Crystal Genomics
• Cytori Therapeutics 

(Note: The list of the major players will be updated with the latest market scenario and trends)

Osteoarthritis Pain Drugs Market Segmentation:

By Drug Class

• NSAIDs
• Opioids
• Viscosupplements
• Corticosteroids
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Dosage Form

• Solid
• Liquid
• Semi-solid

By Application

• Medical Care
• Personal Care

By Region

• North America
• Europe
• Asia Pacific
• Rest of the world

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players 
• Emerging players which are growing rapidly 
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Osteoarthritis Pain Drugs market by drug class, by route of administration, by dosage form, by application and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
        1.1. Objectives of the Study 
        1.2. Market Definition 
        1.3. Market Scope 
               1.3.1. Years Considered for the Study
               1.3.2. Market Covered
        1.4. Currency 
        1.5. Limitations 
        1.6. Stakeholders 
 2.  Research Methodology 
        2.1. Research Data 
               2.1.1. Secondary Data
                          2.1.1.1. Key Data from Secondary Sources
               2.1.2. Primary Data
         2.1.2.1. Key Data from Primary Sources
        2.2. Market Size Estimation 
        2.3. Market Breakdown and Data Triangulation 
        2.4. Assumptions for the Study  
3. Executive Summary
        3.1. Market Outlook
        3.2. Segment Outlook
        3.3. Competitive Insights
4. Global Osteoarthritis Pain Drugs Market Variables, Trends & Scope
        4.1. Market Lineage Outlook
        4.2. Penetration and Growth Prospect Mapping
        4.3. Industry Value Chain Analysis
        4.4. Cost Analysis Breakdown
        4.5. Technology Overview
        4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Osteoarthritis Pain Drugs Market Overview
        5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Osteoarthritis Pain Drugs Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Osteoarthritis Pain Drugs Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
        6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
        6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
        6.4. Market Entry Strategies
        6.5. Case Studies
7. Global Osteoarthritis Pain Drugs Market, By Drug Class Historical Analysis and Forecast 2020-2027 (USD Million)
        7.1. NSAIDs
        7.2. Opioids
        7.3. Viscosupplements
        7.4. Corticosteroids
        7.5. Others
8. Global Osteoarthritis Pain Drugs Market, By Route of Administration Historical Analysis and Forecast 2020-2027 (USD Million)
         8.1 Oral
         8.2 Parenteral
         8.3 Topical
9. Global Osteoarthritis Pain Drugs Market, By Dosage Form Historical Analysis and Forecast 2020-2027 (USD Million)
        9.1. Solid
        9.2. Liquid
        9.3. Semi-solid
10. Global Osteoarthritis Pain Drugs Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
        10.1. Medical Care
        10.2. Personal Care
11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        11.1. Introduction
        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  11.2.1. U.S.A
                  11.2.2. Canada
                  11.2.3. Mexico
        11.3. Market Size (USD Million) Forecast for North America 2020-2027 
12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        12.1. Introduction
        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                 12.2.1. Brazil
                 12.2.2. Venezuela
                 12.2.3. Argentina
                 12.2.4. Rest of Latin America
        12.3. Market Size (USD Million) Forecast for Latin America 2020-2027  
13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        13.1. Introduction
        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  13.2.1. Germany
                  13.2.2. U.K
                  13.2.3. France
                  13.2.4. Italy
                  13.2.5. Spain
                  13.2.6. Russia
                  13.2.7. Poland
                  13.2.8. Rest of Europe
        13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        14.1. Introduction
        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  14.2.1. Japan
                  14.2.2. China
                  14.2.3. India
                  14.2.4. Australia and New Zealand
                  14.2.5. ASEAN
                  14.2.6. Rest of Asia Pacific
        14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
        15.1. Introduction
        15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                  15.2.1. Saudi Arabia
                  15.2.2. UAE
                  15.2.3. South Africa
                  15.2.4. Egypt
        15.3. Market Size (USD Million) Forecast for MEA 2020-2027           
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    16.1 Abbott Laboratories
            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.1.2. Product Portfolio
            16.1.3. SWOT Analysis
            16.1.4. Financial Overview
            16.1.5. Strategic Overview
    16.2 Johnson & Johnson
            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.2.2. Product Portfolio
            16.2.3. SWOT Analysis
            16.2.4. Financial Overview
            16.2.5. Strategic Overview
    16.3 Novartis International
            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2. Product Portfolio
            16.3.3. SWOT Analysis
            16.3.4. Financial Overview
            16.3.5. Strategic Overview
    16.4 Pfizer
            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.4.2. Product Portfolio
            16.4.3. SWOT Analysis
            16.4.4. Financial Overview
            16.4.5. Strategic Overview
    16.5  Abiogen Pharma
            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.5.2. Product Portfolio
            16.5.3. SWOT Analysis
            16.5.4. Financial Overview
            16.5.5. Strategic Overview
    16.6 Afferent Pharmaceuticals
            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.6.2. Product Portfolio
            16.6.3. SWOT Analysis
            16.6.4. Financial Overview
            16.6.5. Strategic Overview
    16.7 Astellas Pharma
            16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.7.2. Product Portfolio
            16.7.3. SWOT Analysis
            16.7.4. Financial Overview
            16.7.5. Strategic Overview
    16.8  BioDelivery Sciences International
            16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.8.2. Product Portfolio
            16.8.3. SWOT Analysis
            16.8.4. Financial Overview
            16.8.5. Strategic Overview
    16.9 Crystal Genomics
            16.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.9.2. Product Portfolio
            16.9.3. SWOT Analysis
            16.9.4. Financial Overview
            16.9.5. Strategic Overview
    16.10 Cytori Therapeutics
            16.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.10.2. Product Portfolio
            16.10.3. SWOT Analysis
            16.10.4. Financial Overview
            16.10.5. Strategic Overview
17. FutureWise SME Key Takeaway Points for Client

Tables

Figures